The LIFE Trial
Losartan Intervention For Endpoint reduction in
hypertension study (LIFE)
Presented at the American College of Cardiology
51st Annual Scientific Session
Atlanta, GA
Dr Björn Dahlöf
for the LIFE Investigators
www. Clinical trial results.org
LIFE: Study Design
Patients with hypertension (blood pressure 160-200/ 95-115 mm Hg)
and left ventricular hypertrophy
Losartan Atenolol
Angiotensin II antagonist Beta-blocker
Dose titrated to BP 4 years - Mean follow-up 4.8 years
Cardiovascular death, MI, stroke
www. Clinical trial results.org
LIFE: Primary Composite Endpoint
Composite of CV Death / MI / Stroke
P=0.021
15%
12.8%
11.0% Adjusted
Hazard
10% Ratio =
0.87
Rate 23.8/1,000 Rate 27.9/1,000
5% patient yrs patient yrs
n=508 n=588
0%
Losartan Atenolol
www. Clinical trial results.org
LIFE: Individual Endpoint Results
Cardiovascular Death Myocardial Infarction Stroke
P=0.206 P=0.491 P=0.001
8% 8% 8%
Adjusted Adjusted Adjusted 6.7%
HR 0.89 HR 1.07 HR 0.75
6% 6% 6%
5.1% 5.0%
4.4% 4.3% 4.1%
4% 4% 4%
2% 2% 2%
0% 0% 0%
Losartan Atenolol Losartan Atenolol Losartan Atenolol
www. Clinical trial results.org
LIFE: New-onset diabetes
P=0.001
10%
8% Adjusted
Hazard 7.0%
Ratio =
6% 0.75
5.2%
4% Rate 13.0/1,000 Rate 17.4/1,000
patient yrs patient yrs
2%
n=241 n=319
0%
Losartan Atenolol
www. Clinical trial results.org